Becton, Dickinson and Company (BDX)
Market Cap | 66.11B |
Revenue (ttm) | 20.64B |
Net Income (ttm) | 1.73B |
Shares Out | 287.14M |
EPS (ttm) | 5.94 |
PE Ratio | 38.75 |
Forward PE | 15.92 |
Dividend | $4.16 (1.81%) |
Ex-Dividend Date | Mar 10, 2025 |
Volume | 2,318,598 |
Open | 231.09 |
Previous Close | 231.85 |
Day's Range | 227.94 - 231.27 |
52-Week Range | 218.75 - 251.99 |
Beta | 0.38 |
Analysts | Strong Buy |
Price Target | 278.29 (+20.88%) |
Earnings Date | May 1, 2025 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system... [Read more]
Financial Performance
In 2024, BDX's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BDX stock is "Strong Buy." The 12-month stock price forecast is $278.29, which is an increase of 20.88% from the latest price.
News

2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...

BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery
FRANKLIN LAKES, N.J. , March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Inves...

Becton, Dickinson and Company (BDX) Barclays 27th Annual Global Healthcare Conference Transcript
Becton, Dickinson and Company (NYSE:BDX) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:30 AM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and President C...

Buy Two Ideal March 'Safer' Dividend Dogs Of 34 Barron's 2025 Pro-Picks
Barron's New-Year (NY) Roundtable (RT) selections published in three issues 1/13-27/2025, listed 34 dividend picks as the best of 2025. Analysts predict top picks like AdvanSix, Applied Materials, and...

The Dividend Aristocrats Ranked By Quality Scores: March 2025
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overval...

Becton, Dickinson and Company (BDX) Citi's 2025 Unplugged Medtech and Life Sciences Access Day Transcript
Becton, Dickinson and Company (NYSE:BDX) Citi's 2025 Unplugged Medtech and Life Sciences Access Day November 27, 2025 8:45 AM ET Company Participants Tom Polen – Chairman, Chief Executive Officer and...

My Best Dividend Aristocrats For March 2025
The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the l...

BD to Present at Investor Healthcare Conferences
FRANKLIN LAKES, N.J. , Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following ...

Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit
Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.

Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript

Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
On Wednesday, Becton, Dickinson and Company BDX authorized to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-or...

Becton Dickinson looks to separate life sciences unit
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.

BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 s...

BD Reports First Quarter Fiscal 2025 Financial Results
Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic GAAP and adjusted diluted EPS of $1.0...

Starboard Value pushes Becton Dickinson to sell life sciences unit, FT reports
Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the medical technology company to sell its life sciences unit, the Financial Times reported on Monday.

BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25
FRANKLIN LAKES, N.J. , Jan. 28, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has decla...

What Can The Dividend Kings Deliver In 2025?
The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by ea...

BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
FRANKLIN LAKES, N.J. and SAN DIEGO , Jan. 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory a...

Carilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of Care
ROANOKE, Va. and FRANKLIN LAKES, N.J.

BD to Announce Financial Results for its First Quarter of Fiscal 2025
FRANKLIN LAKES, N.J. , Jan. 16, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio ...

BD Boosts U.S. Manufacturing of Critical Medical Devices
FRANKLIN LAKES, N.J. , Jan. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional investments in its U.S. man...
Josh Brown's 'best stocks in the market'
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to update his 'best stocks in the market' list.

New ASCCP Guidelines Include More Precise Method of Cervical Cancer Screening
BD Onclarity™ HPV assay adheres to new guidelines by identifying more individual types of HPV than any other test on the market FRANKLIN LAKES, N.J. , Jan. 13, 2025 /PRNewswire/ -- BD (Becton, Dickins...

BD Names Pamela Spikner as Chief Accounting Officer and Controller
FRANKLIN LAKES, N.J., Jan. 10, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Pamela Spikner has been named seni...

New Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer
Women Are Seeking More Convenience and Less Discomfort in Testing Options FRANKLIN LAKES, N.J., Jan. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical ...